

At High Altitude COVID-19 Is Less Frequent: The Experience of Peru*



En la altura la COVID-19 es menos frecuente: la experiencia del Perú

Dear Editor,

Thanks to their ecological plasticity, humans can live anywhere on the planet inhabited by any other animal species.¹ In Peru, a country of 32 million inhabitants, approximately 32% of the population live in regions higher than 2500 m above sea level (masl). However, Peru lies between parallels 0°2' and 18°21'34" of the southern hemisphere, and its proximity to the equator means that the weather is not excessively cold, so humans and other animal and plant species can survive at these heights in conditions of hypobaric hypoxia. According to popular belief in Peru, asthmatics should move to high altitudes because, they say, there is no asthma there. This is because the type of mites found change and their numbers decrease as we ascend, to the extent that they do not exist above 3800 masl.²

The first case of Peruvian COVID-19 was announced on March 7, 2020 and on March 15 the country went into lockdown to curb the pandemic, with curfews still being imposed at the time of writing. Over 170 039 cases of COVID-19 have been confirmed by RT-PCR and IgM/IgG antibodies. An analysis of national data showed that the number of cases and deaths per 100 000 inhabitants decreased as the altitude of residence increased (Fig. 1). Adjusting for sex and region size, the data show that for every 500 m increment in altitude, the rate of cases is reduced by 22% and deaths by 40%. The ratio of cases and deaths in regions below and above 2500 masl is 4.5 and 10.9, with 3450 versus 774 cases and 76 versus 7 deaths, respectively ($P < .05$). It is important to note that above 2600 masl, COVID-19 mortality is estimated at less than 1/100 000 inhabitants

($P < .0001$). This fraction is similar to figures published in Bolivia and Ecuador, which reported 3 to 4-fold lower infection rates at high altitudes than in the lowlands.³

Between 2009 and 2015 in San Jerónimo, Cusco (3244 masl), there were 83 cases of influenza per 1000 person-year, while in Lima, Madre de Dios and Tumbes, located at sea level, there were 107, 108 and 104, respectively, almost 30% fewer cases than at high altitudes.⁴ A lower viral load was observed in mice acclimatized in a hypobaric chamber at a height of 9100 masl who were inoculated with influenza virus, than in their sea level controls (log ID50 4.87 vs 6.97; $P < .01$).⁵ In animals inoculated at a simulated height of 6100 masl, survival was longer in those who remained at that level after inoculation than in those that were returned to sea-level pressures.⁶ The lower frequency of COVID-19 at high altitudes cannot be attributed to hypobaric hypoxia alone, since in Peru the incidence of patients with influenza virus is only 30% lower at high altitude,⁴ whereas the rate of SARS-CoV-2 infection is 350% lower.

To penetrate cells, the S protein of SARS-CoV-2, pre-primed by serine protease TMPRSS2, binds to ACE2.⁷ SARS-CoV-2 preferentially infects well-differentiated ciliated epithelial cells that express ACE2, but not defective cells. In human pulmonary artery smooth muscle cells, overexpression of hypoxia-inducible transcription factor 1 (HIF1) upregulates the expression of the ACE protein and decreases the expression of ACE2. So in hypoxia, HIF1 production is increased, and ACE increases and stimulates the expression of angiotensin II (AT2) which regulates the AT1 receptors, reducing ACE2 expression.⁸ Fewer ACE2 receptors would explain the lower incidence of COVID-19 in high-altitude populations, and also the lower mortality rate, because if fewer ACE2 receptors are circulating, the viral load received by infected subjects, an essential factor in the course of the disease, will be lower.⁹ Hypobaric hypoxia increases erythropoietin (EPO), a multifunctional cytoprotective hormone, which decreases inflammation caused by septic shock and mitigates endotoxemic microvascular damage,¹⁰ factors which




Fig. 1. Inverse relationship between the altitude of residence and the number of cases and deaths per 100 000 inhabitants in the 24 political regions of Peru.

* Please cite this article as: Accinelli RA, Leon-Abarca JA. En la altura la COVID-19 es menos frecuente: la experiencia del Perú. Arch Bronconeumol. 2020;56:760–761.

could also explain the lower COVID-19 mortality among patients living at high altitudes. In France, poor clinical and virological outcomes in COVID-19 patients treated with hydroxychloroquine-azithromycin were associated with the use of AT1 blockers.¹¹ COVID-19-related mortality among men could be higher because ACE2 receptor expression is lower among women.¹²

One of the limitations of this study is that individual data were not used for analysis because they were not freely accessible. More complex research including variables such as age, symptoms, severity, and time-space patterns of infection is needed to determine whether COVID-19 severity varies with altitude.

Although this paper has the limitation that individual data were not used for the analysis because they were not freely accessible, we believe that the pathophysiological mechanisms we describe could explain why in Pasco, the region with the highest capital in Peru (4338 masl), the COVID-19 infection rate is 174/100 000, while in Callao, the lowest capital (7 masl) in the country, it is 1106 (6.4 times higher). We agree with Soliz and Zubieta³ who previously proposed that the lower expression of ACE2 receptors was associated with the reduction of COVID-19 cases among high-altitude residents.

References

1. Roberts P, Amano N. Plastic pioneers: hominin biogeography east of the Movius Line during the Pleistocene. *Archaeol Res Asia*. 2019;17:181–92.
2. Rijssenbeek-Nouwens LH, Bel EH. High-altitude treatment: a therapeutic option for patients with severe, refractory asthma? *Clin Exp Allergy*. 2011;41:775–82.
3. Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, Aliaga-Raudan F, Carvajal-Rodríguez F, Dutschmann M, et al. Does the pathogenesis of SARS-CoV-2 virus decrease at high-altitude? *Respir Physiol Neurobiol*. 2020;277:103443.

4. Tinoco YO, Azziz-Baumgartner E, Uyeki TM, Rázuri HR, Kasper MR, Romero C, et al. Burden of influenza in 4 ecologically distinct regions of Peru: household active surveillance of a community cohort, 2009–2015. *Clin Infect Dis*. 2017;65:1532–41.
5. Kalter SS, Tepperman J. Influenza virus proliferation in hypoxic mice. *Science*. 1952;621–2.
6. Berry LJ, Mitchell RB, Rubenstein D. Effect of acclimatization to altitude on susceptibility of mice to influenza A virus infection. *Proc Soc Exp Biol Med*. 1955;88:543–8.
7. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell*. 2020;181:271–80.e8.
8. Zhang R, Wu Y, Zhao M, Liu C, Zhou L, Shen S, et al. Role of HIF-1 α in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. *Am J Physiol Lung Cell Mol Physiol*. 2009;297:L631–40.
9. Chu CM, Poon LL, Cheng VC, Chan KS, Hung IF, Wong MM, et al. Initial viral load and the outcomes of SARS. *CMAJ*. 2004;171:1349–52.
10. Stoyanoff TR, Rodríguez JP, Todaro JS, Colavita JP, Torres AM, Aguirre MV. Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury. *Biomed Pharmacother*. 2018;107:1046–55.
11. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020:105949.
12. Stelzig KE, Canepa F, Schilliro M, Berdnikovs S, Prakash YS, Chiarella SE. Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells. *Am J Physiol Lung Cell Mol Physiol*. 2020;318:L1280–1.

Roberto Alfonso Accinelli^{a,b,*}, Juan Alonso Leon-Abarca^a

^a Instituto de Investigaciones de la Altura, Universidad Peruana Cayetano Heredia, Lima, Peru

^b Hospital Cayetano Heredia, Lima, Peru

* Corresponding author.

E-mail address: roberto.accinelli@upch.pe (R.A. Accinelli).

Digital Tomosynthesis and COVID-19: An improvement in the assessment of pulmonary opacities[☆]



Tomografía Digital y COVID-19: un avance en la valoración de opacidades pulmonares

To the Editor:

The outbreak of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), emerged in China in late 2019 and was declared a pandemic by the World Health Organization on March 11, 2020. By May 4, 215 countries had already been affected, and more than 3 million cases had been confirmed worldwide.¹ This virus, a member of the Coronaviridae family, uses a spike protein to enter into the cell by binding to the angiotensin-converting enzyme 2 expressed in nasal, oral, lung, and colon cells, amongst other tissues.²

To address this global emergency and facilitate the overall management of this pandemic, the scientific community and health professionals are working on the development of new treatments and technologies to enable early diagnosis. The role of chest imaging, specifically radiography (X-ray) and computed tomography (CT), in the management of patients with suspected COVID-19 should be established taking into account factors such as respi-

ratory disease severity, pretest probability of the disease, and the availability of resources.³

Currently, neither X-ray nor CT are recommended diagnostic criteria for COVID-19. The only accepted diagnostic method is viral screening, with the limitation that quantitative PCR results are only available after 6–48 h. Therefore, although viral testing is still required even when radiological findings are consistent with the disease, radiological imaging findings should be taken into consideration to establish a suspected diagnosis aimed at providing a more efficient triage not only involves screening of patients but also decision like quarantine the patients, admit them etc.^{3,4}

Most publications support the accuracy of CT in detecting viral pneumonia, even in asymptomatic patients.⁵ In patients with a high clinical probability of COVID-19 who are positive on CT but with a negative PCR test, this imaging technique can be viewed as a screening tool, and a repeat PCR is indicated.⁶ The characteristic radiological findings of COVID-19 on CT include multiple peripheral pulmonary opacities, with frequent bilateral involvement, distributed predominantly in basal and posterior regions. X-ray reveals similar characteristics, but the sensitivity of CT is superior.^{7–10}

No uniform criteria are available to guide the radiological evaluation of viral pneumonia in the context of a pandemic. The choice of imaging techniques is based not only on the properties of imaging techniques themselves, but also on the resources of the hospital, the availability of viral testing, expertise, and ultimately depends on the judgement of the team of professionals directly involved in the management of these patients.³

[☆] Please cite this article as: Calvo I, SantaCruz-Calvo S, Aranzana MG, Mármol P, Luque JA, Ramos F, et al. Tomografía Digital y COVID-19: un avance en la valoración de opacidades pulmonares. *Arch Bronconeumol*. 2020;56:761–763.